ProMetic Life Sciences has just announced that it will begin research on the application of their lead pipeline product for pulmonary fibrosis, PBI-4050, in idiopathic pulmonary fibrosis (IPF), an unusual type of PF that leads to spontaneous lung scarring and is estimated to affect over 130,000 Americans. Every…
ProMetic Will Explore PB-4050 Potential as Idiopathic PF Treatment
The U.S. Food and Drug Administration (FDA) recently approved two drugs that are the first therapies specifically directed for the treatment of idiopathic pulmonary fibrosis (IPF) in the United States, Esbriet (pirfenidone), from InterMune, Inc., and OFEV (nintedanib), from…
An influx of research at the University of Colorado, Denver (UCD) concerning the use of Parion Science’s mucolytic agents to treat idiopathic pulmonary fibrosis (IPF), will be made possible by a $7.9 million-total grant from the National Institutes of Health (NIH). According to a press release from…
Idiopathic pulmonary fibrosis (IPF) patients received two pieces of good news just recently when the US Food and Drug Administration announced that it has granted approval for two IPF treatments: Esbriet® (pirfenidone) from InterMune, Inc., and Ofev…
Earlier this month, a second province in Canada finally approved novel pulmonary fibrosis drug Esbriet (pirfenidone) for public funding, which is a giant leap towards improving the lives of thousands of individuals living with idiopathic pulmonary fibrosis…
New Brunswick, Canada residents currently in the fight against a rare and mysterious disease, idiopathic pulmonary fibrosis (IPF), have received new hope after it was announced that the provincial government has added Esbriet (pirfenidone) to the list of treatments publicly funded under the New Brunswick Prescription Drug…
Asbestos exposure has traditionally been linked to Mesothelioma. Now, however, IPF is also being associated with exposure to asbestos in some cases as well. Mesothelioma, a rare type of cancer that affects the protective lining of internal organs, is a common consequence of asbestos exposure. It can…
Seo Hyo-seok, a specialist in Korean traditional medicine, is visiting the United States for a week to promote his unique technique for the treatment of chronic lung conditions like asthma, atopic dermatitis, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). The doctor is the head of the Pyunkang Korean…
Specialty pharmaceutical company Pacific Therapeutics Ltd., known for their strategy on reformulating and improving pre existing FDA-approved drugs, has several leading pipeline products and ongoing research programs targeted at $1 billion dollar markets for erectile dysfunction and pulmonary fibrosis. Recently,…
Emerging product development and commercialization company Allied Minds has just launched a divisional biopharmaceutical company that will specialize in the utilization of a protein called, RHAMM or Receptor for Hyaluronan Mediated Motility, for the creation of products indicated to enhance the body’s natural reparative mechanisms. The company, Novare Pharmaceuticals, is aiming…
